EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, and Vector Pharma FZCO of Dubai UAE, the leading full-service distributor for rare disease, oncology and highly specialized therapeutics in the Middle East, North Africa and Turkish markets, announced a strategic partnership to expand services across the Middle East and North African markets.

GlaxoSmithKline

GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.

hydrocodone

Pharmacy chain Walgreens Boots Alliance and other defendants on April 26 said they were not to blame for the opioid crisis in San Francisco, and that they acted responsibly when providing legal medications to patients in pain.

Johnson & Johnson filed a lawsuit against drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of the company’s HIV drugs, months after a similar case brought by Gilead Sciences Inc.

Novartis’ Sandoz business unit saw a strong financial performance in the first quarter of 2022, with overall sales growth of 8 percent, mostly outside of the United States. Sales for the generics and biosimilar unit benefited from what the company called a normalization of the impacts of COVID-19.

Walgreens Boots Alliance and Teva Pharmaceutical Industries Ltd. ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on April 25 during opening statements of the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.

San Francisco squared off on April 25 against Walgreens Boots Alliance and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.

An experimental treatment from Shionogi & Co. Ltd. has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on April 24.

British employees of pharma giant GlaxoSmithKline voted to strike against the company’s recent pay raise. Hundreds of GSK workers backed by British labor union Unite demanded a higher raise, citing major inflation rates and the company’s recent financial successes.

CureVac and GSK’s second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as the biotech firm seeks to catch up with rivals’ development work.